Alnylam to Webcast Conference Call Discussing Full Results from ILLUMINATE-A Phase 3 Study of Lumasiran at ERA-EDTA Internati...
June 01 2020 - 7:00AM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that management will discuss
full results from the ILLUMINATE-A Phase 3 study of lumasiran in a
webcast conference call on Sunday, June 7, 2020 at 8:30 am ET.
Lumasiran is an investigational RNAi therapeutic targeting
hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase
(GO) – in development for the treatment of primary hyperoxaluria
type 1 (PH1). The clinical data will be presented at a
late-breaking session at the European Renal Association-European
Dialysis and Transplant Association (ERA-EDTA) International
Congress being held June 6-9 as a virtual event.
A live audio webcast of the conference call will be available on
the Investors section of the Company’s website at
www.alnylam.com/events. To access the call, please dial
800-239-9838 (domestic) or +1 323-794-2551 (international) five
minutes prior to the start time and refer to conference ID 6976021.
A replay of the call will be available beginning at 11:30 am ET on
the day of the call. To access the replay, please dial 888-203-1112
(domestic) or +1 719-457-0820 (international) and refer to
conference ID 6976021.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA
interference (RNAi) into a whole new class of innovative medicines
with the potential to transform the lives of people afflicted with
rare genetic, cardio-metabolic, hepatic infectious, and central
nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning
science, RNAi therapeutics represent a powerful, clinically
validated approach for the treatment of a wide range of severe and
debilitating diseases. Founded in 2002, Alnylam is delivering on a
bold vision to turn scientific possibility into reality, with a
robust RNAi therapeutics platform. Alnylam’s commercial RNAi
therapeutic products are ONPATTRO® (patisiran), approved in the
U.S., EU, Canada, Japan, Switzerland and Brazil, and GIVLAARI®
(givosiran), approved in the U.S. and EU. Alnylam has a deep
pipeline of investigational medicines, including six product
candidates that are in late-stage development. Alnylam is executing
on its “Alnylam 2020” strategy of building a multi-product,
commercial-stage biopharmaceutical company with a sustainable
pipeline of RNAi-based medicines to address the needs of patients
who have limited or inadequate treatment options. Alnylam is
headquartered in Cambridge, MA. For more information about our
people, science and pipeline, please visit www.alnylam.com and
engage with us on Twitter at @Alnylam or on LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200601005233/en/
Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors) 617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2023 to Apr 2024